Company profile

OPKO Health

OPK · NASDAQ · USA

Share price · OPK

$1.36+0.23 (+20.35%) 3M

close as of 2026-08-18 · 24h delayed · vol 1.6M

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Extended-release calcifediol(Rayaldee)
Approved
Vitamin D receptor (VDR), via conversion to calcitriolSmall molecule
Chronic Kidney Disease
OPK-88006
Phase 2
GLP-1/glucagon receptor (dual)
MASH / NASH

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.